|
Cyberkinetics Neurotechnology Systems |
|
|
100 Foxborough Boulevard, Suite 240
Foxborough, MA 2035 USA
phone:508-549-9981
fax:508-549-9985 |
| Symbol |
CYKNE |
| Exchange |
.OB |
| Founded |
2001 |
| Employees |
35 |
|
|
| www.cyberkineticsinc.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Therapeutic neurotechnology procedures for the treatment of nervous system conditions, including spinal cord and peripheral nerve injury |
|
| Management |
| TIMOTHY R. SURGENOR,President, Chief Executive Officer and Director; JOHN P. DONOGHUE, Ph.D.,Founder, Chief Scientific Officer and Director; MARK A. CARNEY,Executive Vice President and Director; J. CHRISTOPHER FLAHERTY,Executive Vice President, Technology and Intellectual Property; JONATHAN T. HARTMANN,Vice President, Sales and Marketing; KIMI E. IGUCHI, CPA,Vice President, Finance; KURT H. KRUGER,Chief Financial Officer |
|
|
|
|
| Keywords |
| Neurology, brain, stroke, neuropathy, advamed, nerve, regeneration, repair, neurotechnology, spinal cord |
|
|
|
|
| Description |
|
COMPANY CEASED OPERATIONS IN 2009. Cyberkinetics Neurotechnology Systems, Inc. (OTCBB:CYKN) is focused on commercializing products that restore function for people with a wide range of nervous system conditions and injuries, such as spinal cord injury and peripheral nerve injury. Cyberkinetics' Andara Oscillating Field Stimulator (OFS) Therapy is designed to stimulate the regeneration and repair of nerve fibers, as well as the development of new neural connections, which can potentially restore sensory and motor function. |
|
| Products / Services |
Cyberkinetics' product development pipeline includes: the aforementioned Andara OFS System for acute spinal cord injury; the BrainGate System, an investigative device designed to provide communication with (and control of) a computer, assistive devices and, ultimately, limb movement; and a pilot program to detect and predict the occurrence of epileptic seizures.
|
|
| Technology / Differentiation |
| The company's technology senses the electrical activity of many individual neurons simultaneously. The sensor consists of a small silicon array that contains approximately 100 electrodes. The array is implanted on the surface of the brain. |
|
| Market / Customers |
The program's goal is to create a safe, effective and unobtrusive system for over 400,000 physically disabled people in the U.S. to quickly and reliably control a computer utilizing their thoughts.
|
|
| Status |
| The company acquired Andara Life Science, Inc. in February 2006. The acquisition of Andara's neural stimulation technology positions Cyberkinetics with both neural stimulation and neural sensing capabilities to address central nervous system injuries, diseases and conditions. Cyberkinetics filed a Humanitarian Device Exemption in February 2007 to market its Andara OFS System. Cyberkinetics' NeuroPort Neural Monitoring System, cleared to market in the United States and designed to record and monitor brain electrical activity, as well as potentially predict epileptic seizures, is currently being investigated at Columbia University Medical Center. The BrainGate Neural Interface System, designed to enable paralyzed people control external devices using their thoughts, is currently in clinical trials. |
|
|
|
| |
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
